Upstream Bio plans pivotal Phase 3 trials for verekitug in severe asthma and CRSwNP

Upstream Bio plans pivotal Phase 3 trials for verekitug in severe asthma and CRSwNP
Upstream Bio unveils pivotal trials

Upstream Bio has announced its pivotal Phase 3 development plans for verekitug targeting severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

After regulatory discussions with the U.S. Food and Drug Administration, the company will undertake two separate pivotal trials, each focusing on one of the indications. Both studies will assess a 400mg quarterly regimen of verekitug, with plans to begin enrollment in the first quarter of 2027.

Upstream Bio posted its Q2 2026 results and first indicated plans to launch Phase 3 trials for severe asthma and CRSwNP in early 2027, according to a prior disclosure. Earlier, the company appointed Marie Sanchirico, PhD, MBA, as head of Medical Affairs to strengthen collaboration with medical experts, as reported in a previous announcement. Upstream Bio is moving forward with its development pipeline targeting respiratory and inflammatory conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.